text_1: Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.
text_2: Combining DNA-demethylating agents (DNA methyltransferase inhibitors [DNMTis]) with histone deacetylase inhibitors (HDACis) holds promise for enhancing cancer immune therapy.